Melanoma Clinical Trials

Showing 1241-1260 of 1,477 trials

Intratumoral Administration of L19IL2/L19TNF

NCT02076633

This Phase II study is an uncontrolled, multicenter, prospective study for patients with malignant melanoma of the skin in clinical stage III or stage IV M1a. Twenty Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for up to 4 weeks. The dose will be distributed among the lesions via multiple intralesional injections. The proportion of patients with complete response at week 12 will be calculated.

Malignant Melanoma, Skin

Philogen S.p.A.21 participantsStarted Dec 2012

Milan, Italy • Siena, Italy

TERMINATEDEARLY Phase 1

Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma

NCT02442466

Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788) or vehicle was preformed in 5 melanoma patients to have a preliminary analysis of safety, dose, duration and relevance of results observed in pre-clinical studies to the human disease.

Melanoma

MelCure SA5 participantsStarted May 2011

COMPLETEDPhase 2

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma

NCT01654692

This study is designed to assess the safety and efficacy of a combination of ipilimumab and fotemustine in Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma.

Metastatic Malignant Melanoma

Italian Network for Tumor Biotherapy86 participantsStarted Jun 2010

Genoa, Italy • Meldola, Italy • Milan, Italy +4 more locations

Intratumoral Administration of L19IL2/L19TNF

Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma

Related Searches

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma

Study to Determine if Tissue Scored With a Scalpel Results in Any Noticeable Marks

Comparison Of Video-based Versus Written Patient Education on Sunscreen

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

Skin Cancer Screening and Education at Beaches

Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors